Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cabaletta Bio, Inc. - Common Stock (NQ:CABA)

2.775 +0.085 (+3.16%)
Streaming Delayed Price Updated: 11:21 AM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cabaletta Bio, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces 2026 Strategic Priorities
From Cabaletta Bio
Via GlobeNewswire
News headline image
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
From Cellares
Via Business Wire
News headline image
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces Pricing of Public Offering of Securities
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces Proposed Public Offering of Securities
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
From Cellares
Via Business Wire
News headline image
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
From Cabaletta Bio
Via GlobeNewswire
News headline image
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
From Cabaletta Bio
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.